Profiel
Dr Colas studied molecular biology at the University of Lyon and At the end of 1993, he joined the laboratory of Roger Brent, at the Department of Molecular Biology of Massachusetts General Hospital (Harvard Medical School, Boston, USA), where he contributed to the development of the peptide aptamer technology.
Dr Colas was recruited by the INSERM and came back to Lyon in 1998 to join Dr Rudkin's lab.
He pursued his work on peptide aptamer technologies.
In 2002, Dr Colas took a leave from the INSERM to become Scientific Director of Aptanomics.
Eerdere bekende functies van Pierre Colas
| Bedrijven | Functie | Einde |
|---|---|---|
Aptanomics SA
 Aptanomics SA Pharmaceuticals: MajorHealth Technology Aptanomics SA discovers and develops new drugs in major markets of unmet medical need. Its proprietary discovery engine, based on peptide aptamers, delivers a regular flow of new hits against relevant industrial targets. Aptanomics offers opportunities for drug discovery collaborations leveraging the peptide aptamer technology to identify new druggable sites and screen for small molecule hits. The company was founded by Roger Brent, Pierre Colas and Johm B. Hawken in 2001 and is headquarters in Lyon, France | Hoofd Techniek/Wetenschap/O&O | 24-01-2008 |
Opleiding van Pierre Colas
| École Normale Supérieure de Lyon | Doctorate Degree |
| Ecole Centrale Lyon | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
Aptanomics SA
Aptanomics SA Pharmaceuticals: MajorHealth Technology Aptanomics SA discovers and develops new drugs in major markets of unmet medical need. Its proprietary discovery engine, based on peptide aptamers, delivers a regular flow of new hits against relevant industrial targets. Aptanomics offers opportunities for drug discovery collaborations leveraging the peptide aptamer technology to identify new druggable sites and screen for small molecule hits. The company was founded by Roger Brent, Pierre Colas and Johm B. Hawken in 2001 and is headquarters in Lyon, France | Health Technology |
